Authors: | Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y. Q.; Greil, R.; Mykhalska, L.; Burgués, J. M. B.; Cheung, M. C.; Pinto, A.; Shin, H. J.; Hapgood, G.; Munhoz, E.; Salles, G. |
Abstract Title: | Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study |
Meeting Title: | 2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung |
Journal Title: | Oncology Research and Treatment |
Volume: | 45 |
Issue: | Suppl. 3 |
Meeting Dates: | 2022 Nov 13-16 |
Meeting Location: | Berlin, Germany |
ISSN: | 2296-5270 |
Publisher: | S. Karger AG |
Date Published: | 2022-11-01 |
Start Page: | 164 |
Language: | English |
ACCESSION: | WOS:000883051700384 |
PROVIDER: | wos |
DOI: | 10.1159/000521004 |
Notes: | Meeting Abstract: 891 -- Source: Wos |